Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology [Seeking Alpha]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Seeking Alpha
Ziihera's Phase 3 data surpassing Herceptin signals a transformative 'pipeline in a product' opportunity, targeting multi-billion-dollar HER2+ cancer market. Zepzelca's expanded front-line SCLC approval and Epidiolex's blockbuster trajectory underpin near-term revenue growth and portfolio diversification. I rate JAZZ a Strong Buy, with 2026 a transitional year supporting long-term asymmetric upside as the narrative shifts to growth in oncology. zamrznutitonovi/iStock via Getty Images Jazz Pharmaceuticals plc ( JAZZ ) is a global biopharmaceutical company headquartered in Dublin, Ireland. While its best-selling neuroscience drug, Xywav, treats narcolepsy, the company is undergoing a robust pivot into oncology with two emerging assets: Ziihera and Zepzelca. This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of JAZZ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.MarketBeat
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.MarketBeat
- Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain [Yahoo! Finance]Yahoo! Finance
- Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 11/5/25 - Beat
JAZZ
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 4
- 12/11/25 - Form 4
- JAZZ's page on the SEC website